$HALB Halberd's Traumatic Brain Injury (TBI) Testi
Post# of 630
(Total Views: 122)
Posted On: 10/04/2023 10:04:10 AM
$HALB Halberd's Traumatic Brain Injury (TBI) Testing Results Replicated at Mississippi State University (MSU)
https://www.accesswire.com/789795/halberds-tr...ersity-msu
JACKSON CENTER, PA / ACCESSWIRE / October 4, 2023 / Halberd Corporation's (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing:
25% reduction in Neuron Specific Enolase and
52.3% reduction in the levels of Glial Fibrillary Acid Protein
compared to the control group.
Neuron Specific Enolase (NSE) is a biomarker of neuronal damage and is a known predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is a widely used indicator of ongoing neurodegeneration resulting from traumatic brain injury. Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
Mitchell S. Felder, M.D., Halberd Corporation's Chief Technology Officer and a board-certified attending neurologist, stated, "I believe that the Halberd nasal spray could be a major breakthrough in the treatment of TBI and possibly other neurological disease states. The nasal spray in our testing reduced NSE (Neuron Specific Enolase) by 4.1% at day 3, and 29.2% at day 6 in the study! There was also a profound improvement in GFAP (Glial Fibrillary Acidic Protein) of 25.0% at day 3, and 52.3% at day 6 in the test subject animals! GFAP is used by physicians worldwide for the diagnosis, treatment and prognosis of TBI. This has the potential for greatly changing the prognosis in TBI victims."
Dr. Felder continued, "For now, the objective is to perfect the formulation for the best possible outcome. The present results are demonstrably beneficial and incredibly encouraging. We look forward to feedback from the Department of Defense as to further strategies, while we continue this study at MSU."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, remarked, "The results from these replication tests at MSU are very encouraging and indicate that we are on the right track to finding an effective treatment in mitigating the effects of TBI, particularly with timely administration and even when administered within two weeks of the injury. The nasal spray has the unique potential for self-administration within minutes of a TBI incident, when the victim is in a remote location. Our objective is to be able to provide an effective, easy-to-use, point of incidence treatment for TBI to ameliorate the chemical imbalance in the brain, which can lead to numerous neurodegenerative diseases and suicide ideation."
https://www.accesswire.com/789795/halberds-tr...ersity-msu
JACKSON CENTER, PA / ACCESSWIRE / October 4, 2023 / Halberd Corporation's (OTC PINK:HALB) proprietary nasal spray testing results to mitigate the effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU) replicated the earlier dramatic results. The latest testing results were very similar to the initial proof of concept testing:
25% reduction in Neuron Specific Enolase and
52.3% reduction in the levels of Glial Fibrillary Acid Protein
compared to the control group.
Neuron Specific Enolase (NSE) is a biomarker of neuronal damage and is a known predictor of the ultimate outcomes of TBI. Glial Fibrillary Acid Protein (GFAP) is a widely used indicator of ongoing neurodegeneration resulting from traumatic brain injury. Reductions of NSE and GFAP are associated with better neurological outcomes from head trauma.
Mitchell S. Felder, M.D., Halberd Corporation's Chief Technology Officer and a board-certified attending neurologist, stated, "I believe that the Halberd nasal spray could be a major breakthrough in the treatment of TBI and possibly other neurological disease states. The nasal spray in our testing reduced NSE (Neuron Specific Enolase) by 4.1% at day 3, and 29.2% at day 6 in the study! There was also a profound improvement in GFAP (Glial Fibrillary Acidic Protein) of 25.0% at day 3, and 52.3% at day 6 in the test subject animals! GFAP is used by physicians worldwide for the diagnosis, treatment and prognosis of TBI. This has the potential for greatly changing the prognosis in TBI victims."
Dr. Felder continued, "For now, the objective is to perfect the formulation for the best possible outcome. The present results are demonstrably beneficial and incredibly encouraging. We look forward to feedback from the Department of Defense as to further strategies, while we continue this study at MSU."
William A. Hartman, Chairman, President and CEO of Halberd Corporation, remarked, "The results from these replication tests at MSU are very encouraging and indicate that we are on the right track to finding an effective treatment in mitigating the effects of TBI, particularly with timely administration and even when administered within two weeks of the injury. The nasal spray has the unique potential for self-administration within minutes of a TBI incident, when the victim is in a remote location. Our objective is to be able to provide an effective, easy-to-use, point of incidence treatment for TBI to ameliorate the chemical imbalance in the brain, which can lead to numerous neurodegenerative diseases and suicide ideation."
(0)
(0)Halberd Corporation (HALB) Stock Research Links
Scroll down for more posts ▼